https://www.selleckchem.com/products/MDV3100.html
Repurposing drug and immunomodulators used in combination could reduce the severity of EV-A71 infection. Only a few drugs have been tested in clinical trials, and in the absence of antiviral and vaccines (except China), active virus surveillance, good hand hygiene, and physical distancing should be advocated. A better understanding of EV-A71 neuropathogenesis is critical for antiviral and multivalent vaccines development. Although it is reported that patients with coronavirus disease 2019 (COVID-19) disease who have comorbidities are at
Like
Comment
Share
